Life Sciences
10/25/21
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
7/19/21
MINDERA™ ANNOUNCES PUBLICATION OF AN ECONOMIC EVALUATION OF PRECISION MEDICINE TESTING FOR THE TREATMENT OF PSORIASIS
6/17/21
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A for Commercialization of Bentracimab
6/15/21
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
4/27/21
Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory
3/2/21
G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
2/12/21
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
12/18/20
Castle Biosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/9/20
G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium
10/8/20
Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma
10/6/20
PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab
7/27/20
Mindera Corporation Announces Appointment of George W. Mahaffey as President and Chief Executive Officer
6/24/20
Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock
5/27/20
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients
1/13/20
PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension
1/10/20
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® forPB2452
11/21/19
AN2 Therapeutics Launches with $12 Million in Series A Funding and Announces a Strategic Partnership with Brii Biosciences
10/29/19
Castle Biosciences Presents Clinical Validation Study for its Cutaneous Squamous Cell Carcinoma Prognostic Test at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting
10/15/19
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
10/7/19
Newly Published Systematic Review Confirms Strength of Evidence and Outlines Appropriate Use Criteria for Integration of DecisionDx-Melanoma in Management of Patients with Cutaneous Melanoma
9/4/19
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314
8/14/19
PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452
7/29/19
Castle Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
6/18/19
G1 THERAPEUTICS ANNOUNCES UPDATED RESULTS FROM PHASE 2 TRIAL OF TRILACICLIB IN COMBINATION WITH CHEMOTHERAPY SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL IN WOMEN WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER
6/17/19
PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects
4/29/19
G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020
3/17/19
Full Results from PhaseBio Phase I Clinical Trial Published in New England Journal of Medicine
3/6/19
Publication of Independent Prospective, Multicenter Study Reinforces Accuracy of DecisionDx-Melanoma Test Recurrence Risk Prediction
2/7/19
Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck
1/30/19
Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions
1/7/19
Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study
12/6/18
Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to its Board of Directors
10/18/18
Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma
7/30/18
Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis
6/28/18
APPELLO COMPLETES $10.5 MILLION SERIES A FINANCING LED BY DEERFIELD MANAGEMENT AND MOUNTAIN GROUP PARTNERS
5/31/18
Clearside Biomedical Announces Positive Topline Results from Phase 2 Clinical Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema
4/16/18
G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
3/28/18
Castle Biosciences Announces Inclusion of DecisionDx-UM Prognostic Test in New NCCN Guidelines for Uveal Melanoma
3/15/18
G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Bene ts in Patients with Small Cell Lung Cancer
3/5/18
Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis
5/30/17
G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting
5/25/17
FUTURE Local Coverage Determination for MolDX: DecisionDxUM (Uveal Melanoma) (L37033)
3/29/17
G1 Therapeutics Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting
12/5/16
G1 Therapeutics to Evaluate Trilaciclib (G1T28) in Combination with Immune Checkpoint Inhibitor in Small-Cell Lung Cancer
9/21/16
NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis
4/26/16
Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients with Macular Edema Associated with Retinal Vein Occlusion
12/14/15
Clearside Biomedical, Inc. Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space (SCS™) Drug Administration
12/10/15
NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment
1/15/15
Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial For the Treatment of Macular Edema Associated With Non-Infectious Uveitis
7/7/14